Drug Trial Radar · NCT04623671
Intravenous Infusion of CAP-1002 in Patients With COVID-19
Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Nov 15, 2020
Primary completion
Feb 4, 2022
Study completion Feb 4, 2022
Sponsor
- Lead sponsor
- Capricor Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.
Conditions
- Covid19
Interventions
CAP-1002Biological
Peripheral infusion of 150 million cardiosphere-derived cells (CDCs)
PlaceboBiological
Matching placebo solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of CAP-1002: Incidence of All-Cause MortalityTime frame: Up to End of Study (Day 90)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of California Davis
Sacramento, California
Henry Ford Health System
Detroit, Michigan
PharmaTex Research, LLC
Amarillo, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.